Trial intelligence / Profile preview

DCC-2618 in Advanced Gastrointestinal Stromal Tumor After Prior Therapy

CTR20192728Phase 2Completed

Sponsor
Akeso Biopharma
Start
Feb 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Akeso Biopharma. Started Feb 2020; status: completed.

02

Drugs

ripretinib
03

Conditions

gastrointestinal stromal tumor (GIST)

Beyond the preview

Go deeper on CTR20192728.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20192728.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call